Scarica l'app Stockscreener
14.79
5.12%
0.72
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MLTX Giù?
Forum
Previsione
Precedente Chiudi:
$14.07
Aprire:
$14.24
Volume 24 ore:
2.36M
Relative Volume:
0.48
Capitalizzazione di mercato:
$1.05B
Reddito:
-
Utile/perdita netta:
$-145.21M
Rapporto P/E:
-6.4304
EPS:
-2.3
Flusso di cassa netto:
$-140.12M
1 W Prestazione:
-0.74%
1M Prestazione:
+15.82%
6M Prestazione:
-66.40%
1 anno Prestazione:
-72.49%
Intervallo 1D:
$14.10
$14.98
Intervallo di 1 settimana:
$13.87
$15.55
Portata 52W:
$5.95
$62.75
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Nome
Moonlake Immunotherapeutics
Settore
Industria
Telefono
41 41 510 8022
Indirizzo
DORFSTRASSE 29, ZUG
Confronta MLTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
14.79 | 996.82M | 0 | -145.21M | -140.12M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-03 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-10-02 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-10-01 | Downgrade | Goldman | Buy → Neutral |
| 2025-09-30 | Downgrade | Citigroup | Buy → Neutral |
| 2025-09-30 | Downgrade | Wolfe Research | Outperform → Underperform |
| 2025-09-29 | Downgrade | BTIG Research | Buy → Neutral |
| 2025-09-29 | Downgrade | Jefferies | Buy → Hold |
| 2025-09-29 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-29 | Downgrade | Stifel | Buy → Hold |
| 2025-07-28 | Iniziato | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-01-17 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-11-05 | Ripresa | Wedbush | Outperform |
| 2024-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Iniziato | Oppenheimer | Outperform |
| 2024-04-02 | Iniziato | Goldman | Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-08 | Iniziato | Citigroup | Buy |
| 2023-11-02 | Iniziato | Stifel | Buy |
| 2023-09-14 | Downgrade | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | Iniziato | Needham | Buy |
| 2023-06-15 | Iniziato | Barclays | Equal Weight |
| 2023-05-01 | Iniziato | Guggenheim | Buy |
| 2023-03-22 | Iniziato | Wedbush | Outperform |
| 2023-03-09 | Iniziato | BTIG Research | Buy |
| 2023-02-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-02 | Iniziato | Bryan Garnier | Buy |
| 2022-11-11 | Iniziato | Jefferies | Buy |
| 2022-08-25 | Iniziato | SVB Leerink | Outperform |
| 2022-07-21 | Iniziato | H.C. Wainwright | Buy |
| 2022-07-07 | Iniziato | Cowen | Outperform |
Mostra tutto
Moonlake Immunotherapeutics Borsa (MLTX) Ultime notizie
MOONLAKE CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C. - GlobeNewswire
MLTX FRAUD UPDATE: Important MoonLake Immunotherapeutics Securities Fraud Class Action Deadline is Approaching for Investors – Contact BFA Law before December 15 - GlobeNewswire Inc.
Deadline Soon: MoonLake Immunotherapeutics (MLTX) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - The AI Journal
MoonLake Immunotherapeutics Sued for Securities Law - GlobeNewswire
MLTX Deadline: MLTX Investors with Losses in Excess of $100K Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit - marketscreener.com
MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Announces That MoonLake Immunotherapeutics Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit - NewMediaWire
MLTX Investor Deadline Alert: MoonLake (MLTX) Class Action LawsuitHagens Berman Scrutinizing Nanobody Superiority Claims After 90% Plunge; December Lead Plaintiff Deadline Looms - PR Newswire
MLTX DEADLINE: Faruqi & Faruqi Reminds MoonLake Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025MLTX - PR Newswire
Holzer & Holzer, LLC Reminds Investors of Upcoming Lead - GlobeNewswire
MLTX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics ... - Caledonian Record
MLTX 4-DAY DEADLINE ALERT: MoonLake (MLTX) Class Action Lawsuit – - The National Law Review
MLTX 4-DAY DEADLINE ALERT: MoonLake (MLTX) Class Action - GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP - GlobeNewswire
MLTX Investors Have Opportunity to Lead MoonLake - GlobeNewswire
MoonLake Immunotherapeutics Class Action: The Gross Law Firm Reminds MoonLake Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025MLTX - PR Newswire
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Top Executives Cash In on MoonLake Immunotherapeutics Stock! - TipRanks
MoonLake Immunotherapeutics(MLTX.US) Officer Sells US$3.01 Million in Common Stock - 富途牛牛
Understanding the Setup: (MLTX) and Scalable Risk - news.stocktradersdaily.com
Deadline Alert: MoonLake Immunotherapeutics (MLTX) - GlobeNewswire
Ready to Jump After Recent Trade: MoonLake Immunotherapeutics (MLTX) - setenews.com
MLTX DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important December 15 Deadline in Securities Class ActionMLTX - marketscreener.com
MLTX 6-DAY DEADLINE ALERT: MoonLake Immunotherapeutics (MLTX) Fa - GuruFocus
MLTX 6-DAY DEADLINE ALERT: MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman - PR Newswire
DEADLINE ALERT for MLTX, BAX, and JHX: The Law Offices of - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of MoonLake Immunotherapeutics, Inc. Investors - GlobeNewswire
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
SueWallSt Podcast Series Launches With Focus on MoonLake Immunotherapeutics (MLTX) Fraud Allegations - ACCESS Newswire
Marshall Wace LLP Sells 111,706 Shares of MoonLake Immunotherapeutics $MLTX - MarketBeat
Shareholders SueWallSt in New Class Action Against MoonLake ImmunotherapeuticsAct Now - ACCESS Newswire
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash - AOL.com
MLTX DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important December 15 Deadline in Securities Class ActionMLTX - marketscreener.com
MLTX 1-WEEK DEADLINE ALERT: MoonLake Immunotherapeutics - GlobeNewswire
MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - marketscreener.com
MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) SHAREHOLDER - GlobeNewswire
Contact The Gross Law Firm by December 15, 2025 Deadline to Join Class Action Against MoonLake Immunotherapeutics(MLTX) - Sahm
2025-12-07 | Did You Lose Money on MoonLake Immunotherapeutics (MLTX)? Levi & Korsinsky Urges Investors to Act Before December 15, 2025 | NDAQ:MLTX | Press Release - Stockhouse
MLTX INVESTOR LOSSES: Lose Money on MoonLake - GlobeNewswire
MLTX 9-DAY DEADLINE ALERT: MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman - GlobeNewswire
MLTX SECURITIES ALERT: BFA Law Reminds MoonLake Immunotherapeutics Investors with Losses of Important December 15 Securities Class Action Deadline - marketscreener.com
Are MoonLake (MLTX) Securities Lawsuits Quietly Reframing the Credibility of Its Drug Innovation Story? - simplywall.st
Class Action Filed Against MoonLake Immunotherapeutics (MLTX) Se - GuruFocus
Class Action Filed Against MoonLake Immunotherapeutics (MLTX) Seeking Recovery for InvestorsContact Levi & Korsinsky - PR Newswire
MLTX FINAL DEADLINE: ROSEN, A LONGSTANDING LAW FIRM, Encourages MoonLake Immunotherapeutics Investors with Losses in Excess of $100K to Secure Counsel Before Important December 15 Deadline in Securities Class ActionMLTX - marketscreener.com
Deadline Alert: MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - GlobeNewswire
MoonLake Immunotherapeutics Target of Unusually Large Options Trading (NASDAQ:MLTX) - MarketBeat
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics - Morningstar
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Why MoonLake Immunotherapeutics (MLTX) Is Up 9.2% After Lawsuits Challenging Sonelokimab Claims And What's Next - Yahoo Finance
MoonLake Immunotherapeutics (MLTX) Valuation After Class Action Lawsuits and Sonelokimab Trial Setbacks - simplywall.st
Levi & Korsinsky Helps Shareholders SueWallSt After MoonLake Immunotherapeutics Stock Drops - ACCESS Newswire
Moonlake Immunotherapeutics Azioni (MLTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Moonlake Immunotherapeutics Azioni (MLTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Santos da Silva Jorge | Chief Executive Officer |
Dec 09 '25 |
Sale |
14.49 |
70,000 |
1,014,300 |
2,878,577 |
| Reich Kristian | Chief Scientific Officer |
Dec 08 '25 |
Sale |
15.08 |
130,000 |
1,960,400 |
72,908 |
| Reich Kristian | Chief Scientific Officer |
Dec 09 '25 |
Sale |
14.43 |
72,908 |
1,052,062 |
0 |
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):